Graphene Composites Ltd (GC) is pleased to announce an international collaboration with ZEN (ZEN) (TSXV:ZEN) to fight COVID-19 by developing a potential virucidal graphene-based composite ink that can be applied to fabrics including N95 face masks and other personal protective equipment (PPE) for significantly
increased protection. Once the development, testing, and confirmation of the graphene ink’s virucidal ability have been completed, the ink will then be incorporated into fabrics used for PPE.
Sandy Chen, CEO of GC stated, “Combining the deep nanomaterials expertise of GC and ZEN with a truly collaborative approach has enabled us to do a year’s worth of R&D in a matter of weeks. Quickly developing and deploying our virucidal/germicidal ink would make a significant difference in slowing the rate of infection – thus saving many lives.”
Francis Dubé, CEO of ZEN commented, “We are pleased to be collaborating with GC and be on the forefront of a new innovative technology that could contribute to combating the deadly COVID-19 virus. The development of this potential COVID-19 virucidal graphene ink is coming at a crucial time to provide effective PPE supplies for the safety of frontline workers and hospital staff.” Dr. Dubé continued, “The current N95 masks trap the virus but don’t kill it. Our testing will demonstrate if the graphene ink is an effective virucide which would kill the virus as this could make a big difference to people’s safety. We have been very impressed by the Graphene Composites team and look forward to continued collaborations.”
Under the collaboration, GC have devised a silver nanoparticle/graphene oxide ink formulation that ZEN has synthesized at their lab in Guelph, Ontario, that has been documented by previous researchers to kill earlier versions of coronavirus.
Once testing is completed, the GC/ZEN graphene ink would then be incorporated into a fabric to be included into masks and filters designed by GC. Efficacy testing of the silver-graphene oxide-based ink to kill the COVID 19 virus (SARS-CoV-2) will be conducted at the University of Western Ontario ImPaKT Facility Biosafety Level 3 lab.
In addition, the graphene ink will be tested to kill influenza A and B viruses at Biosafety Level 2 labs in the UK and US.